221 related articles for article (PubMed ID: 26631752)
1. BH4 domain of Bcl-2 as a novel target for cancer therapy.
Liu Z; Wild C; Ding Y; Ye N; Chen H; Wold EA; Zhou J
Drug Discov Today; 2016 Jun; 21(6):989-96. PubMed ID: 26631752
[TBL] [Abstract][Full Text] [Related]
2. Antagonizing Bcl-2's BH4 domain in cancer.
Vervloessem T; La Rovere R; Bultynck G
Aging (Albany NY); 2015 Oct; 7(10):748-9. PubMed ID: 26525307
[No Abstract] [Full Text] [Related]
3. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
de Ridder I; Kerkhofs M; Veettil SP; Dehaen W; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118983. PubMed ID: 33549704
[TBL] [Abstract][Full Text] [Related]
4. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
Vervloessem T; Sasi BK; Xerxa E; Karamanou S; Kale J; La Rovere RM; Chakraborty S; Sneyers F; Vogler M; Economou A; Laurenti L; Andrews DW; Efremov DG; Bultynck G
Cell Death Dis; 2020 Sep; 11(9):769. PubMed ID: 32943617
[TBL] [Abstract][Full Text] [Related]
5. Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain.
Gabellini C; Trisciuoglio D; Del Bufalo D
Carcinogenesis; 2017 Jun; 38(6):579-587. PubMed ID: 28203756
[TBL] [Abstract][Full Text] [Related]
6. Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain.
Zhou JY; Yang RR; Chang J; Song J; Fan ZS; Zhang YH; Lu CH; Jiang HL; Zheng MY; Zhang SL
Acta Pharmacol Sin; 2023 Feb; 44(2):475-485. PubMed ID: 35918411
[TBL] [Abstract][Full Text] [Related]
7. CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth.
Lin Y; Zhao Y; Chen M; Li Z; Liu Q; Chen J; Ding Y; Ding C; Ding Y; Qi C; Zheng L; Li J; Zhang R; Zhou J; Wang L; Zhang QQ
BMC Cancer; 2023 May; 23(1):479. PubMed ID: 37237269
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics investigations of structural and functional changes in Bcl-2 induced by the novel antagonist BDA-366.
Li T; Cui Y; Wu B
J Biomol Struct Dyn; 2019 Jul; 37(10):2527-2537. PubMed ID: 30047840
[TBL] [Abstract][Full Text] [Related]
9. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
Deng J; Park D; Wang M; Nooka A; Deng Q; Matulis S; Kaufman J; Lonial S; Boise LH; Galipeau J; Deng X
Oncotarget; 2016 May; 7(19):27753-63. PubMed ID: 27049723
[TBL] [Abstract][Full Text] [Related]
10. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP
Ivanova H; Luyten T; Decrock E; Vervliet T; Leybaert L; Parys JB; Bultynck G
Cell Calcium; 2017 Mar; 62():41-46. PubMed ID: 28179071
[TBL] [Abstract][Full Text] [Related]
11. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
Monaco G; La Rovere R; Karamanou S; Welkenhuyzen K; Ivanova H; Vandermarliere E; Di Martile M; Del Bufalo D; De Smedt H; Parys JB; Economou A; Bultynck G
FEBS J; 2018 Jan; 285(1):127-145. PubMed ID: 29131545
[TBL] [Abstract][Full Text] [Related]
12. Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth.
Trisciuoglio D; De Luca T; Desideri M; Passeri D; Gabellini C; Scarpino S; Liang C; Orlandi A; Del Bufalo D
Neoplasia; 2013 Mar; 15(3):315-27. PubMed ID: 23479509
[TBL] [Abstract][Full Text] [Related]
13. Challenges in small-molecule target identification: a commentary on "BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models".
Birkinshaw RW
Cell Death Differ; 2021 Mar; 28(3):1130-1132. PubMed ID: 33469228
[No Abstract] [Full Text] [Related]
14. Cross Talk Between Cellular Redox State and the Antiapoptotic Protein Bcl-2.
Pohl SÖ; Agostino M; Dharmarajan A; Pervaiz S
Antioxid Redox Signal; 2018 Nov; 29(13):1215-1236. PubMed ID: 29304561
[TBL] [Abstract][Full Text] [Related]
15. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
Rong YP; Barr P; Yee VC; Distelhorst CW
Biochim Biophys Acta; 2009 Jun; 1793(6):971-8. PubMed ID: 19056433
[TBL] [Abstract][Full Text] [Related]
16. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Bcl-2.
Patel MP; Masood A; Patel PS; Chanan-Khan AA
Curr Opin Oncol; 2009 Nov; 21(6):516-23. PubMed ID: 19730103
[TBL] [Abstract][Full Text] [Related]
18. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
19. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
Raghav PK; Verma YK; Gangenahalli GU
Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
[TBL] [Abstract][Full Text] [Related]
20. Targeting BCL-2 regulated apoptosis in cancer.
Campbell KJ; Tait SWG
Open Biol; 2018 May; 8(5):. PubMed ID: 29769323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
